Pharmacokinetics, safety, and tolerability of PSI 7851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2012
At a glance
- Drugs PSI 7851 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Pharmasset
- 09 Jun 2009 Status changed from recruiting to completed, according to a Pharmasset media release.
- 20 Apr 2009 The first antiviral data are expected to be reported in the second half of 2009, according to a Pharmasset media release.
- 06 Apr 2009 New trial record.